Barcelona, May 5, 2020 - Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), has announced today it has completed the development of a specific TMA (Transcription-Mediated Amplification) molecular test that permits the detection of the SARS-CoV-2 virus in plasma, blood and respiratory samples, with a sensitivity equal or even superior to that of other molecular tests currently available, such as those based on PCR.

Thanks to this high sensitivity, the molecular test will also permit testing of pools of samples (pool strategy), multiplying the capacity of testing the population.

The TMA test is a complete and automated testing solution that includes all the reagents, from the preparation of the sample to getting a result. It is processed on Procleix® Panther® systems, each unit with an analysis capacity of more than 1,000 samples daily.

'Having sufficient molecular test capacity is critical to helping control this pandemic, and having a high-sensitivity test to handle a possible 'pooling' strategy is, without a doubt, a differentiating factor, which could make it feasible,' said Victor Grifols Deu, Grifols co-CEO.

Attachments

  • Original document
  • Permalink

Disclaimer

Grifols SA published this content on 05 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 May 2020 05:58:03 UTC